JNJ-79635322, JNJ-79635322
79635322MMY2001
Phase 2 small_molecule active
Quick answer
JNJ-79635322, JNJ-79635322 for Relapsed or Refractory Multiple Myeloma (RRMM) is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active